Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

By afschroeder • October 8, 2025

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy. Front Oncol. 2025 Sep 22;15:1649493. doi: 10.3389/fonc.2025.1649493. PMID: 41059291; PMCID: PMC12497632.

Tags: antagonists, clinical efficacy, combination drug therapy, drug administration schedules, exportin 1, Hematology/Oncology, inhibitors, Multiple myeloma, Publications, selinexor

Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

Zhang R, Qi J, McKasson M, Choi J, Gutierrez V, Brennan C, Hong S, Chour W, Ng RH, Xie J, Yuan D, Webster A, Sidhu[...]

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy

Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase[...]

Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care Coordination in Safety-Net Systems

Tupper HI, Doo FX, Lin Y, Flores EJ, Salinas DA, Cummings AL, Ryan GW, Revels SL. Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care[...]